High Serum LDH & ALP Levels: Poor Prognostic Indicators for Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a type of cancer originating in the nasopharynx, the upper part of the throat behind the nose. While rare in most parts of the world, it's more common in regions like Southeast Asia, North Africa, and the Middle East.

Several factors influence NPC prognosis, including cancer stage, patient age and overall health, and blood biomarker levels. Two such biomarkers are serum lactate dehydrogenase (LDH) and alkaline phosphatase (ALP).

LDH is an enzyme present in various tissues, including the liver, heart, and muscles. When cells are damaged, LDH is released into the bloodstream, leading to elevated blood levels. ALP, primarily found in the liver and bones, indicates potential liver or bone damage when its blood levels increase.

Numerous studies have linked elevated pretreatment LDH and ALP levels to poorer NPC prognosis. For instance, a 2015 study published in Cancer Science revealed that patients with high pretreatment LDH levels had significantly lower overall survival rates compared to those with low levels. Similarly, a 2016 study in the Journal of Cancer linked high pretreatment ALP levels to a higher risk of distant metastasis and poorer overall survival.

These findings suggest that pretreatment LDH and ALP levels can serve as valuable biomarkers for predicting NPC prognosis. Patients with high levels of these biomarkers might require more aggressive treatment and closer monitoring to enhance their outcomes.